TargeGen
TargeGen, Inc. was a San Diego-based biopharmaceutical company founded in 2002 developing small molecule kinase inhibitors for vascular biology indications. It raised approximately $113.7M across five funding rounds through 2009; its corporate domain is currently listed for sale.
- Company typePrivate
- Founded2002
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What TargeGen does
TargeGen, Inc. was a San Diego-based biopharmaceutical company founded in 2002 that focused on vascular biology and the discovery and development of small molecule kinase inhibitors. The company operated with a headcount of 11-50 employees and built a pipeline of small molecule therapeutics targeting kinase pathways implicated in vascular disease. Its underlying technology centered on medicinal chemistry and kinase selectivity screening to identify orally bioavailable drug candidates, though specific platform architecture, lead assets, or clinical-stage programs are not disclosed in the source data.
The company's capital structure reflects a typical clinical-stage biotech build: approximately $113.7 million was raised across five documented financing events between May 2002 and September 2009, with investors including Forward Ventures, Enterprise Partners, BB Biotech Ventures, CDP Capital Technology Ventures, William Blair, Innovis Investments, Pappas Ventures, and VantagePoint Capital Partners. The largest round, $40 million, closed in July 2007, followed by a sharp reduction to a ~$3.7 million bridge in September 2009. No further capital events, product launches, partnership announcements, or operational signals are present in the available data, and the company's corporate web domain (targegen.com) is currently listed for sale on DomainMarket.com for $8,888.
As a pre-revenue drug developer, TargeGen's business model relied on advancing candidates through preclinical and clinical milestones toward eventual out-licensing, partnership, or corporate exit; the firm had no commercial products, and its only documented leadership signal is a single director. The combination of a stalled funding cadence after 2009 and an active domain-for-sale listing indicates the entity is no longer operating as an independent going concern.
TargeGen firmographics
Firmographics- Name
- TargeGen
- Website
- https://targegen.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TargeGen, Inc. was a San Diego-based biopharmaceutical company founded in 2002 developing small molecule kinase inhibitors for vascular biology indications. It raised approximately $113.7M across five funding rounds through 2009; its corporate domain is currently listed for sale.
- Ownership category
- akta.pro rank
TargeGen industry classification
Industry- Product category
- Biopharmaceutical R&D
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where TargeGen is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
TargeGen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Domain name sale: One-time sale of premium domain name TargeGen.com for $8,888. After transfer, buyer receives full ownership with no ongoing fees.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Premium domain TargeGen.com - single one-time purchase |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
TargeGen product offering
Product offeringCore offering
TargeGen, Inc. is a vascular biology-focused biopharmaceutical company that discovers and develops small molecule kinase inhibitors as therapeutic candidates. The company applies vascular biology expertise to identify and advance kinase-targeting drug candidates aimed at cardiovascular and related disease indications. Its core work spans early-stage drug discovery through preclinical and clinical development of small molecule compounds.
Product overview
TargeGen.com is a single premium domain asset being sold through DomainMarket.com. The offering consists of one domain name rather than a platform or modular product suite. There are no additional products, modules, or add-on services associated with this listing.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule Kinase Inhibitor Program
Quantifiable outcome
- Domain gains immediate search ranking advantage from keyword-rich naming
Companies that use TargeGen
Customer profileSegments1 record
Ideal customer profiles1 record
TargeGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TargeGen partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
TargeGen competitors and assessment
Company assessmentDirect peers
- Exelixis: Exelixis developed cabozantinib, a multi-kinase inhibitor with vascular and oncology applications, making it a directly comparable platform-based kinase company that successfully brought assets through to commercialization.
- Incyte Corporation: Incyte developed ruxolitinib (JAKAFI), the first FDA-approved JAK inhibitor for myeloproliferative neoplasms, directly competing with TargeGen's lead TG101348 program in the same indication and mechanism.
- Plexxikon: Plexxikon developed vemurafenib (Zelboraf) and other small molecule kinase inhibitors from a structure-based discovery platform — a directly comparable kinase-focused biotech that was acquired by Daiichi Sankyo.
- Cytopia Research: Cytopia was an Australian small molecule kinase inhibitor company focused on JAK2 and other oncology targets, with comparable scale, geography of operations, and therapeutic focus to TargeGen in the same era.
- YM BioSciences: YM BioSciences developed momelotinib and other JAK inhibitors for myeloproliferative neoplasms, making it one of the closest contemporaneous competitors to TargeGen in vascular and hematologic kinase targets.
- Array BioPharma: Array BioPharma built a broad small molecule kinase inhibitor pipeline (MEK, BRAF, FGFR) before being acquired by Pfizer in 2019, sharing the same platform-centric kinase strategy as TargeGen at similar development stage.
- ARIAD Pharmaceuticals: ARIAD developed small molecule kinase inhibitors (ponatinib, brigatinib) for oncology indications, representing a comparable kinase-focused biopharma acquired by Takeda in 2017.
- S*BIO Pte Ltd: S*BIO was a Singapore-based clinical-stage biopharma developing small molecule kinase inhibitors (including JAK and SYK inhibitors) in oncology and inflammation — a directly comparable small-molecule, kinase-focused, mid-stage peer.
Broad incumbents
- OSI Pharmaceuticals: OSI Pharmaceuticals commercialized erlotinib (Tarceva), a small molecule kinase inhibitor, making it a relevant incumbent in the kinase inhibitor space that overlapped with TargeGen's mechanistic approach.
Emerging players
- Astex Therapeutics: Astex applied fragment-based drug discovery to develop small molecule kinase inhibitors, sharing the structural biology-driven, small molecule approach of TargeGen's platform in similar therapeutic areas.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
TargeGen social profiles
Digital presenceTargeGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
TargeGen leadership team
Management profileNumber of profiles
Profiles1 record
TargeGen funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TargeGen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TargeGen
What does TargeGen do?
TargeGen, Inc. is a vascular biology-focused biopharmaceutical company that discovers and develops small molecule kinase inhibitors as therapeutic candidates. The company applies vascular biology expertise to identify and advance kinase-targeting drug candidates aimed at cardiovascular and related disease indications. Its core work spans early-stage drug discovery through preclinical and clinical development of small molecule compounds.
Is TargeGen a public or private company?
TargeGen is a private company. It is classified as venture growth investor backed and is currently operating.
When was TargeGen founded?
TargeGen was founded in 2002. It employs 11 to 50 people.
Where is TargeGen based?
TargeGen is headquartered in San Diego, United States, in the North America region.
How does TargeGen make money?
One revenue line is on record: domain name sale.
Who are TargeGen's main competitors?
Direct peers on record are Exelixis, Incyte Corporation, Plexxikon, Cytopia Research, YM BioSciences, Array BioPharma, ARIAD Pharmaceuticals and S*BIO Pte Ltd. OSI Pharmaceuticals is listed as a broad incumbent. Astex Therapeutics is listed as an emerging player.
Does TargeGen have an API?
No public API is recorded for TargeGen.
What industry is TargeGen in?
TargeGen's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation).